Weekly Roundup: Are you ready for Jefferies and London Life Sciences Week?🚨

Commit Biologics nominates first development candidate from BiCE™, its complement system engaging platform, and strengthens senior leadership

Commit Biologics (“Commit”), the biotechnology company pioneering complement-powered immune engagers, announced the nomination of its first development candidate, COM002, as well as making two senior appointments, as it transitions from platform discovery to clinical development. COM002 will initially be developed to target relapsed/refractory non-Hodgkin lymphoma, with plans to expand the candidate into several autoimmune indications.

 

SITC: Combinations of iOnctura’s roginolisib revert immune suppression in immunotherapy-resistant NSCLC

iOnctura, a clinical-stage precision oncology company combating neglected and hard-to-treat cancers, presented positive late-breaking data from its Phase I/II PULMO-01 trial, evaluating combinations of its conformation-selective PI3Kδ inhibitor roginolisib in patients with immunotherapy-resistant NSCLC, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.

 

DeepLife and 3billion partner to discover and develop small-molecule therapeutics against genetic modifier targets across multiple diseases

DeepLife, a Paris-based techbio company developing AI-powered digital twins of human cells, and 3billion, a South Korean  AI-powered genomics company specializing in rare disease diagnostics and drug discovery, announced a co-development collaboration to discover and develop new small-molecule therapeutics against novel targets, with a focus on genetic modifiers.

 

AC Immune to present at Jefferies Global Healthcare Conference 2026

AC Immune SA, a clinical-stage biopharma company targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases, announced that Martin Zügel, Interim CEO, will present and participate in a fireside chat at the annual Jefferies Global Healthcare Conference 2026, taking place November 16-19 in London, UK.

 

Hansa Biopharma announced Q3 and interim year to date financial results, and participation at Jefferies Global Healthcare Conference in London

Hansa Biopharma announced its interim report for the three and nine months ended September 30, 2026.

The Company also announced that its CEO Renée Aguiar-Lucander, will participate in a fireside chat with Farzin Haque, Biotechnology Equity Research Analyst, Jefferies, at the Jefferies Global Healthcare Conference in London, on Tuesday 17 November, at 14:00-14:25 GMT / 09:00-09:25 EST. Hansa Biopharma COO and President US Maria Törnsén, CFO Adam Cutler, CMO Richard Philipson, and VP Business Development Fredrik Röök will also be attending the event.

 

TECregen strengthens management team and Board to advance thymus regeneration and lead program TEC001

TECregen, a biotechnology company pioneering thymus regeneration to restore immune function, announced the appointment of Elisabeth Svanberg, MD, PhD, as Chief Medical Officer and Thomas Hanke, PhD, to its Board of Directors. Dr. Hanke succeeds Martin Raditsch, PhD, as CARMA FUND’s representative on the Board. The appointments strengthen the company as it advances TEC001, its lead program designed to rebuild thymic function and increase the production of new naïve T cells.

 

DaltonTx appoints Melissa Landon as Chief Commercial Officer to drive commercial growth and strategic partnerships

DaltonTx, the decision engine for drug discovery, announced the appointment of Melissa Landon, Ph.D., as Chief Commercial Officer to lead the company’s commercial strategy. Dr Landon joins DaltonTx to drive adoption of its platform across pharma, biotech and CROs.

 

🎥 Optimum TV

London Life Science Week

This week on #OptimumTV, Zoe Bolt, Associate Director at Optimum Strategic Communications, speaks with Mary Clark, CEO of Optimum, and Arnaldo De Lisio, Managing Partner at Catalyst Advisors LP, about how to get the most out of one of the busiest weeks in the life sciences calendar. They share practical advice on prioritising meetings and building meaningful connections, and highlight the Official London Life Sciences Week Networking Event Guide, created by Optimum and Catalyst with participation from Jefferies, to help attendees navigate the week’s key events.

Watch the episode for the full conversation:

Atrogi

New on #OptimumTV, Atrogi CEO Paul Little joins host Isabelle Abdou to discuss whether a pill can really mimic the effects of exercise.

Paul shares the company’s recent human data for its lead candidate, ATR-258, which showed increased lean muscle mass, reduced fat mass and improved muscle function, including an approximately 13% increase in lower-leg muscle power. He explains why these results are an important step for Atrogi, how ATR-258 is designed to activate the same cellular processes as exercise, and the company’s plans to explore its potential in muscle-wasting conditions such as #FSHD.

Watch the episode for the full conversation:

👥Industry events

 

BIO-Europe 2026 – Cologne, Germany | 9-11 Nov

Thank you to everyone we met at BIO-Europe 2026. Our CEO, Mary Clark, and Associate Director, Zoe Bolt, enjoyed connecting with companies, investors and potential partners across the global biotech community.

 

Jefferies Global Healthcare Conference & London Life Sciences Week
London | 15-20 November 2026

Next week is one of the busiest in the life sciences calendar, and the Official Networking Event Guide is now live. Produced by Optimum Strategic Communications and Catalyst Advisors LP in partnership with Jefferies, it brings together the key receptions, workshops, panel discussions, networking events and industry gatherings taking place across the week.

🔗👉 [VIEW THE OFFICIAL NETWORKING EVENT GUIDE]

Start planning your schedule today so you don’t miss out.

 

5K London Landmarks Run | 17 November 2026

There’s still time to sign up. With 50+ people already registered, it’s shaping up to be a great networking opportunity. Join Optimum Strategic Communications and Catalyst Advisors LP on Tuesday 17th of November for an early morning run through some of London’s most iconic landmarks, kicking off a busy week of meetings and events during London Life Sciences Week and the Jefferies Global Healthcare Conference.

👉 Sign up here

 

📅 Save the date!

Optimum’s 19th Annual Healthcare Investor Conference returns on 7 October 2027 — and we’re celebrating our 10-year anniversary!

Expect an unmissable day of bold ideas, valuable connections and lively debate as the life sciences and investment communities come together once again. Save the date—more details coming soon!

That’s all folks!  To stay in the know – subscribe to Optimum’s weekly wrap-up today!

 

© Optimum Strategic Communications.